Ayrshire Capital Management LLC raised its position in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 12.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 3,354 shares of the medical research company’s stock after purchasing an additional 380 shares during the period. Ayrshire Capital Management LLC’s holdings in Amgen were worth $811,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dixon Hughes Goodman Wealth Advisors LLC lifted its position in shares of Amgen by 905.2% in the 1st quarter. Dixon Hughes Goodman Wealth Advisors LLC now owns 1,156 shares of the medical research company’s stock worth $280,000 after purchasing an additional 1,041 shares during the period. Boston Partners lifted its position in shares of Amgen by 57.1% in the 4th quarter. Boston Partners now owns 1,135,035 shares of the medical research company’s stock worth $255,349,000 after purchasing an additional 412,337 shares during the period. Avantax Advisory Services Inc. increased its stake in shares of Amgen by 2.1% in the 4th quarter. Avantax Advisory Services Inc. now owns 30,188 shares of the medical research company’s stock valued at $6,793,000 after acquiring an additional 613 shares in the last quarter. O ROURKE & COMPANY Inc bought a new stake in shares of Amgen in the 4th quarter valued at $260,000. Finally, Cullinan Associates Inc. increased its stake in shares of Amgen by 2.2% in the 4th quarter. Cullinan Associates Inc. now owns 197,501 shares of the medical research company’s stock valued at $44,432,000 after acquiring an additional 4,345 shares in the last quarter. Hedge funds and other institutional investors own 79.01% of the company’s stock.
AMGN has been the subject of several research analyst reports. SVB Leerink initiated coverage on shares of Amgen in a research note on Monday, May 23rd. They issued a “market perform” rating and a $256.00 price objective for the company. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 16th. TheStreet lowered shares of Amgen from a “b+” rating to a “c+” rating in a research note on Wednesday, April 27th. Morgan Stanley decreased their price target on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 12th. Finally, Mizuho boosted their price target on shares of Amgen from $202.00 to $208.00 in a research note on Tuesday, May 10th. One analyst has rated the stock with a sell rating, ten have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $242.57.
In other Amgen news, Director R Sanders Williams sold 600 shares of the company’s stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $250.00, for a total transaction of $150,000.00. Following the sale, the director now directly owns 5,501 shares of the company’s stock, valued at $1,375,250. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Jonathan P. Graham sold 13,500 shares of the company’s stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total transaction of $3,264,435.00. Following the sale, the executive vice president now directly owns 37,333 shares in the company, valued at $9,027,492.73. The disclosure for this sale can be found here. 0.46% of the stock is currently owned by insiders.
Shares of NASDAQ:AMGN opened at $243.51 on Wednesday. The company’s 50-day moving average is $243.89 and its 200-day moving average is $235.77. The company has a debt-to-equity ratio of 39.31, a quick ratio of 1.09 and a current ratio of 1.44. The company has a market capitalization of $130.08 billion, a P/E ratio of 23.97, a price-to-earnings-growth ratio of 2.10 and a beta of 0.57. Amgen Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $258.45.
Amgen (NASDAQ:AMGN – Get Rating) last issued its quarterly earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $4.22 by $0.03. The company had revenue of $6.24 billion for the quarter, compared to the consensus estimate of $6.09 billion. Amgen had a net margin of 21.75% and a return on equity of 165.95%. During the same period in the previous year, the firm earned $3.70 EPS. As a group, research analysts predict that Amgen Inc. will post 17.44 earnings per share for the current year.
About Amgen: (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due to a low white blood cell count in cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for prevention of skeletal-related events; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.